SynCardia Systems
SynCardia Systems is a medical technology company.
- Company typePublic
- Founded2001
- HeadquartersTucson, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What SynCardia Systems does
SynCardia Systems is the privately-held manufacturer of Total Artificial Heart. The SynCardia temporary Total Artificial Heart (TAH) is used as a bridge to transplant, helping them survive until a matching donor heart. becomes available.
SynCardia Systems firmographics
Firmographics- Name
- SynCardia Systems
- Legal name
- SynCardia Systems, LLC.
- Website
- http://www.syncardia.com/
- Company type
- Public
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- SynCardia Systems is a medical technology company.
- Ownership category
- akta.pro rank
SynCardia Systems industry classification
Industry- Product category
- Total Artificial Heart Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)
- akta.pro secondary industry
- Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)
Keywords
Where SynCardia Systems is headquartered
LocationHeadquarters
- HQ city
- Tucson
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
SynCardia Systems business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- SynCardia Total Artificial Heart Device Sales: Revenue from the sale of SynCardia Total Artificial Heart ventricles and associated components to transplant centers. Full-year 2025 revenue was $4.94 million, a 12.5% increase year-over-year.
- Freedom Driver Rental Program: Rental revenue from the Freedom Driver portable system used by eligible patients discharged from hospital while awaiting transplant. Q1 2026 revenue of $1.2M was driven by growth in both product revenue and the Freedom Driver rental program.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
SynCardia Systems product offering
Product offeringCore offering
SynCardia Systems develops, manufactures, and sells the SynCardia Total Artificial Heart (STAH), the only FDA- and Health Canada-approved total artificial heart commercially available in the U.S. and Canada. The company offers the device in two ventricle sizes (70cc and 50cc) along with two pneumatic driver systems—the Companion 2 (C2) for in-hospital use and the Freedom Driver for outpatient mobility—and is developing the next-generation fully implantable Emperor Drive System.
Product overview
SynCardia Systems manufactures a unified product ecosystem centered on the SynCardia Total Artificial Heart (STAH), the world's first and only FDA-approved total artificial heart. The portfolio includes two sizes of the artificial heart (70cc and 50cc) and two driver systems: the Companion 2 Driver for in-hospital use and the Freedom Driver for portable outpatient support. The company is developing next-generation platforms including the Emperor Drive System (a fully implantable electromechanical driver) and Unicorn (driver miniaturization), both currently investigational.
Differentiator
Problem solved
Functional benefit
Brands
- SynCardia Total Artificial Heart (STAH): FDA-approved total artificial heart for bridge-to-transplant in patients with end-stage biventricular heart failure
- Companion 2 Driver (C2)
- Freedom Driver
- Emperor
Products and services
- SynCardia Total Artificial Heart (STAH) FDA-approved total artificial heart that replaces both failing ventricles and all four native heart valves for transplant-eligible patients at risk of imminent death from biventricular heart failure. Available in 70cc and 50cc ventricle sizes.
- Companion 2 Driver (C2) In-hospital pneumatic driver system with touchscreen controls that powers the implanted SynCardia Total Artificial Heart following surgery, designed for operating room, ICU, and step-down care settings.
- Freedom Driver Portable pneumatic driver system that powers the SynCardia Total Artificial Heart, allowing eligible patients to be discharged from hospital while awaiting transplant. Battery-powered with backpack and shoulder carry options for patient mobility.
- Emperor Drive System (EDS) Next-generation patent-pending electromechanical actuation platform for the SynCardia Total Artificial Heart, designed to replace external pneumatic drivers and advance toward a fully implantable system. Investigational and not yet approved for commercial sale.
Quantifiable outcome
- Over 2,100 SynCardia Total Artificial Heart implants performed across 27 countries
- +2 more outcomes
Companies that use SynCardia Systems
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles1 record
SynCardia Systems technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature4 records
SynCardia Systems partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Houston Methodist HospitalcorePicard Medical and SynCardia hosted an invitation-only surgical training program at Houston Methodist Hospital on February 24, 2026, bringing together cardiac surgeons and clinical teams from four Houston-area heart centers for education on SynCardia Total Artificial Heart implantation techniques, patient selection, and clinical best practices. The training combined classroom instruction with hands-on surgical training and is part of Picard's broader strategy to develop centers of excellence and expand adoption of total artificial heart therapy at leading transplant centers nationwide.
- Hydrix ServicescoreSynCardia Systems (subsidiary of Picard Medical) entered into a development collaboration agreement with Hydrix Services on January 5, 2026, to advance the Emperor next-generation fully implantable total artificial heart. Hydrix performs development work through the end of 2026 as a first phase of a broader multi-stage, multi-year program. The agreement is structured around defined engineering verification and regulatory milestones, with continuation between stages dependent on technical progress and safety validation. Picard Medical noted the collaboration may allow the company to benefit from Australian R&D tax incentives of approximately 43% of eligible expenditure.
- Picard Medical, Inc. (parent company)corePicard Medical, Inc. is the parent company and sole owner of SynCardia Systems LLC. SynCardia operates as a wholly owned subsidiary. Picard Medical is publicly traded on NYSE American under ticker symbol PMI. The parent company completed its IPO on September 2, 2025, raising approximately $19.5 million in gross proceeds.
Scale indicators8 records
Recent moves9 records
Expansion highlights5 records
SynCardia Systems competitors and assessment
Company assessmentDirect peers
- Carmat: French-listed developer of the Aeson total artificial heart, the only commercially-relevant TAH competitor to SynCardia. Carmat is CE-marked in Europe and competes in the same bridge-to-transplant clinical niche.
- Berlin Heart: Manufacturer of the EXCOR pediatric and adult ventricular assist devices. Competes with SynCardia in the bridge-to-transplant mechanical support category, particularly for smaller-patient anatomies.
Broad incumbents
- Abbott: Owner of HeartMate 3 LVAD, the dominant left-ventricular assist device. Competes with SynCardia in the mechanical circulatory support space but does not offer a total artificial heart — they are the most likely alternative therapy at U.S. transplant centers.
- Abiomed (Johnson & Johnson MedTech): Acquired by J&J in 2022, Abiomed manufactures the Impella family of percutaneous ventricular support devices. Operates in adjacent mechanical circulatory support indications and shares SynCardia's transplant-center customer base.
- Medtronic: Historical developer of the HeartWare HVAD (recalled 2021). Medtronic remains a major player in cardiac surgery, heart valves, and mechanical circulatory support infrastructure and competes for share-of-mind with cardiac surgeons.
- LivaNova: Manufactures the TandemHeart percutaneous ventricular assist system and has historical presence in cardiopulmonary products. Operates in adjacent mechanical circulatory support space with shared hospital customers.
- Edwards Lifesciences: Dominant player in surgical heart valves and transcatheter valve replacement. Competes indirectly for cardiac surgery OR time and budget at transplant centers, and could expand into mechanical circulatory support adjacencies.
- Getinge (Maquet): Provides intra-aortic balloon pumps (IABP), ECMO systems, and operating-room infrastructure used at transplant centers. Competes for mechanical circulatory support share of clinical workflow at the same hospital customers.
Emerging players
- Jarvik Heart: Developer of next-generation continuous-flow total artificial heart and ventricular assist devices. Investigational-stage competitor with a similar long-term goal to SynCardia's Emperor program.
Others
- Fresenius Medical Care: While not a direct TAH competitor, Fresenius operates cardiovascular services adjacent to transplant and advanced heart failure programs and participates in the same hospital ecosystem where SynCardia implants occur.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
SynCardia Systems social profiles
Digital presenceSynCardia Systems compliance and trust
Trust signalCompliance2 records
SynCardia Systems financial estimates
Financial estimateRevenue estimate
Valuation estimate
SynCardia Systems leadership team
Management profileNumber of profiles
Profiles9 records
SynCardia Systems funding detail
Funding detailFunding overview
Funding rounds4 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SynCardia Systems M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SynCardia Systems
What does SynCardia Systems do?
SynCardia Systems develops, manufactures, and sells the SynCardia Total Artificial Heart (STAH), the only FDA- and Health Canada-approved total artificial heart commercially available in the U.S. and Canada. The company offers the device in two ventricle sizes (70cc and 50cc) along with two pneumatic driver systems—the Companion 2 (C2) for in-hospital use and the Freedom Driver for outpatient mobility—and is developing the next-generation fully implantable Emperor Drive System.
Is SynCardia Systems a public or private company?
SynCardia Systems is a public company. It is classified as corporate owned and is currently operating.
When was SynCardia Systems founded?
SynCardia Systems was founded in 2001. It employs 101 to 250 people.
Where is SynCardia Systems based?
SynCardia Systems is headquartered in Tucson, United States, in the North America region.
How does SynCardia Systems make money?
Two revenue lines are on record. SynCardia Total Artificial Heart Device Sales are the primary driver. The others are freedom Driver Rental Program.
Who are SynCardia Systems's main competitors?
Direct peers on record are Carmat and Berlin Heart. Broad incumbents are Abbott, Abiomed (Johnson & Johnson MedTech), Medtronic, LivaNova, Edwards Lifesciences and Getinge (Maquet). Jarvik Heart is listed as an emerging player. Fresenius Medical Care is listed as an others.
Does SynCardia Systems have an API?
No public API is recorded for SynCardia Systems.
What industry is SynCardia Systems in?
SynCardia Systems's product category is Total Artificial Heart Medical Devices. Its primary akta.pro industry code is HLAHAFAG, Mechanical Circulatory Support (VAD, IABP, ECMO), with a secondary code of HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation). Its NAICS code is 334510 and its SIC code is 3845.